NCT05648994View on ClinicalTrials.gov

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

March 31, 2026

Conditions
Solid Tumors
Interventions
BIOLOGICAL

TCR-T cells

patients will be administration of TCR-T cells

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regime

DRUG

Cyclophosphamide Capsules

Part of the non-myeloablative lymphocyte-depleting preparative regime

DRUG

Albumin-bound paclitaxel

Part of the non-myeloablative lymphocyte-depleting preparative regime

DRUG

IL-2

Following cell infusion, the patient will be administration high-dose IL-2.

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT05648994 - TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | Biotech Hunter | Biotech Hunter